Charles M. Winter net worth and biography

Charles Winter Biography and Net Worth

Insider of Janux Therapeutics

Charles is Chief Technical Officer at Janux, where he leads all aspects of process development and manufacturing from preclinical through commercialization. Charles brings to Janux more than 25 years of bioprocess experience for leading biotechnology and pharmaceutical companies and has played vital roles in bringing more than 20 molecules into clinical development and six to market, including Avastin^®, Herceptin^®, Rituxan^®, and Xolair^®. Charles started his career at Genentech where he spent 17 years in increasing roles of responsibility in bioprocess development and CMC leadership from preclinical through development and commercialization. After Genentech, he was Director of Biologics Development at Gilead, building biologics development and CMC platforms, capabilities and strategies. Charles then become Vice President of Manufacturing and Technology for JHL Biotech in Taiwan, running its cGMP contract manufacturing plant. Prior to joining Janux, Charles held senior leadership roles running outsourced CMC programs at Denali Therapeutics, Synthorx (now a Sanofi company), and AnaptysBio.

Charles received a B.S. in chemical engineering from the University of Wisconsin-Madison.

What is Charles M. Winter's net worth?: The estimated net worth of Charles M. Winter is at least $1.03 million as of January 2nd, 2026. Winter owns 77,721 shares of Janux Therapeutics stock worth more than $1,026,694 as of February 18th. This net worth approximation does not reflect any other assets that Winter may own. Additionally, Winter receives a salary of $590,400.00 as Insider at Janux Therapeutics. Learn More about Charles M. Winter's net worth.
How old is Charles M. Winter?: Winter is currently 55 years old. There are 5 older executives and no younger executives at Janux Therapeutics. The oldest executive at Janux Therapeutics is Dr. David Alan Campbell Ph.D., President, CEO & Director, who is 64 years old. Learn More on Charles M. Winter's age.
What is Charles M. Winter's salary?: As the Insider of Janux Therapeutics, Inc., Winter earns $590,400.00 per year. There are 2 executives that earn more than Winter. The highest earning executive at Janux Therapeutics is Dr. David Alan Campbell Ph.D., President, CEO & Director, who commands a salary of $1,040,000.00 per year. Learn More on Charles M. Winter's salary.
How do I contact Charles M. Winter?: The corporate mailing address for Winter and other Janux Therapeutics executives is , , . Janux Therapeutics can also be reached via phone at 858-751-4493 and via email at [email protected]. Learn More on Charles M. Winter's contact information.
Has Charles M. Winter been buying or selling shares of Janux Therapeutics?: During the last quarter, Charles M. Winter has sold $32,965.73 in Janux Therapeutics stock. Most recently, Charles M. Winter sold 2,401 shares of the business's stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $13.73, for a transaction totalling $32,965.73. Following the completion of the sale, the insider now directly owns 77,721 shares of the company's stock, valued at $1,067,109.33. Learn More on Charles M. Winter's trading history.
Who are Janux Therapeutics' active insiders?: Janux Therapeutics' insider roster includes David Campbell (Founder, President & CEO), Thomas Diraimondo (Insider), Maria Dobek (VP), Zachariah Mciver (Insider), Andrew Meyer (Chief Business Officer), and Charles Winter (Insider). Learn More on Janux Therapeutics' active insiders.
Are insiders buying or selling shares of Janux Therapeutics?: During the last year, Janux Therapeutics insiders bought shares 2 times. They purchased a total of 451,948 shares worth more than $13,889,565.00. During the last year, insiders at the sold shares 12 times. They sold a total of 52,365 shares worth more than $1,286,149.42. The most recent insider tranaction occured on January, 2nd when insider Thomas Diraimondo sold 2,505 shares worth more than $34,393.65. Insiders at Janux Therapeutics own 29.4% of the company. Learn More about insider trades at Janux Therapeutics.
Information on this page was last updated on 1/2/2026.

Charles M. Winter Insider Trading History at Janux Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/2/2026	Sell	2,401	$13.73	$32,965.73	77,721

Charles M. Winter Buying and Selling Activity at Janux Therapeutics

Janux Therapeutics Company Overview

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Today's Range

Now: $13.45

$13.16

$13.53

50 Day Range

MA: $13.93

$12.18

$15.58

2 Week Range

Now: $13.45

$12.12

$38.42

Volume

125,837 shs

Average Volume

1,536,274 shs

Market Capitalization

$808.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.88

Charles Winter Biography and Net Worth

What is Charles M. Winter's net worth?

How old is Charles M. Winter?

What is Charles M. Winter's salary?

How do I contact Charles M. Winter?

Has Charles M. Winter been buying or selling shares of Janux Therapeutics?

Who are Janux Therapeutics' active insiders?

Are insiders buying or selling shares of Janux Therapeutics?